Search results
22 maj 2020 · Our data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection....
- Original Article Colchicine in Patients With Chronic Coronary Disease S.M. Nidorf and Others
The on-treatment analysis was performed in patients who had...
- Free Full Text
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the...
- Images in Clinical Medicine Auricular Hematoma A.L. Miller and M.S. Cohen
A 17-year-old boy presented with swelling and bruising of...
- Original Article Lineage-Independent Tumors in Bilateral Neuroblastoma T.H.H. Coorens and Others
Remdesivir for the Treatment of Covid-19 — Final Report....
- Interactive Medical Case a Patient With Fever and Dyspnea W.R. Matias and Others
This interactive case features a 60-year-old woman who...
- Perspective Shaping The Future of Veterans' Health Care L. McCauley and K.S. Ramos
Members of the U.S. military are at risk for a range of...
- Clinical Problem-Solving In The Absence of Proof S. Kushwaha and Others
Guidelines for treatment of drug-susceptible tuberculosis...
- Images in Clinical Medicine Necrotizing Scleritis N. Lorenzana Blanco and N. Alejandre Alba
A 73-year-old woman with rheumatoid arthritis presented with...
- Original Article Colchicine in Patients With Chronic Coronary Disease S.M. Nidorf and Others
Patients with mild-to-moderate disease who are at high risk for progression to severe COVID-19 . Treatment with remdesivir for three days in ambulatory patients reduced hospitalizations and COVID-19-related medically attended visits throughout day 28 (HR: 0.28; 95% CI: 0.1, 0.75, low CoE; and HR: 0.19; 95% CI: 0.07, 0.56, low CoE, respectively).
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized...
Remdesivir is an adenosine nucleotide analogue prodrug that abrogates viral replication by inducing chain termination after its incorporation into the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (RdRp) enzyme [2].
5 lis 2020 · Methods: We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days ...
Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy. Treatment guidelines should be re-evaluated.
22 kwi 2022 · Pfizer’s oral antiviral drug (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe COVID-19 who are at highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients.
